220 related articles for article (PubMed ID: 35706041)
1. Neoadjuvant immunotherapy across cancers: meeting report from the Immunotherapy Bridge-December 1st-2nd, 2021.
Burton EM; Amaria RN; Cascone T; Chalabi M; Gross ND; Mittendorf EA; Scolyer RA; Sharma P; Ascierto PA
J Transl Med; 2022 Jun; 20(1):271. PubMed ID: 35706041
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant immunotherapy of locoregionally advanced solid tumors.
Tarhini AA; Eads JR; Moore KN; Tatard-Leitman V; Wright J; Forde PM; Ferris RL
J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 35973745
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN).
Ahern E; Cubitt A; Ballard E; Teng MWL; Dougall WC; Smyth MJ; Godbolt D; Naidoo R; Goldrick A; Hughes BGM
Trials; 2019 Dec; 20(1):753. PubMed ID: 31856909
[TBL] [Abstract][Full Text] [Related]
4. Current status and future perspectives on immunotherapy in neoadjuvant therapy of resectable non-small cell lung cancer.
Liu X; Xing H; Liu H; Chen J
Asia Pac J Clin Oncol; 2022 Aug; 18(4):335-343. PubMed ID: 34811893
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant immunotherapy for non-small cell lung cancer: right drugs, right patient, right time?
Ahern E; Solomon BJ; Hui R; Pavlakis N; O'Byrne K; Hughes BGM
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34083418
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant and Neoadjuvant Immunotherapy in Non-small Cell Lung Cancer.
Broderick SR
Thorac Surg Clin; 2020 May; 30(2):215-220. PubMed ID: 32327180
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant immunotherapy in gastrointestinal cancers - The new standard of care?
Petricevic B; Kabiljo J; Zirnbauer R; Walczak H; Laengle J; Bergmann M
Semin Cancer Biol; 2022 Nov; 86(Pt 2):834-850. PubMed ID: 35671877
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant Immunotherapy for High-Risk, Resectable Malignancies: Scientific Rationale and Clinical Challenges.
Krishnamoorthy M; Lenehan JG; Maleki Vareki S
J Natl Cancer Inst; 2021 Jul; 113(7):823-832. PubMed ID: 33432320
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant Immunotherapy for Locally Advanced Melanoma.
Pelster MS; Amaria RN
Curr Treat Options Oncol; 2020 Feb; 21(2):10. PubMed ID: 32025932
[TBL] [Abstract][Full Text] [Related]
10. Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd - 4th, 2021, Italy).
Ascierto PA; Agarwala SS; Blank C; Caracò C; Carvajal RD; Ernstoff MS; Ferrone S; Fox BA; Gajewski TF; Garbe C; Grob JJ; Hamid O; Krogsgaard M; Lo RS; Lund AW; Madonna G; Michielin O; Neyns B; Osman I; Peters S; Poulikakos PI; Quezada SA; Reinfeld B; Zitvogel L; Puzanov I; Thurin M
J Transl Med; 2022 Sep; 20(1):391. PubMed ID: 36058945
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant immunotherapy is reshaping cancer management across multiple tumour types: The future is now!
Maio M; Blank C; Necchi A; Di Giacomo AM; Ibrahim R; Lahn M; Fox BA; Bell RB; Tortora G; Eggermont AMM
Eur J Cancer; 2021 Jul; 152():155-164. PubMed ID: 34107449
[TBL] [Abstract][Full Text] [Related]
12. Perspectives in Immunotherapy: meeting report from the Immunotherapy Bridge, December 1st-2nd, 2021.
Ascierto PA; Avallone A; Bhardwaj N; Bifulco C; Bracarda S; Brody JD; Buonaguro L; Demaria S; Emens LA; Ferris RL; Galon J; Khleif SN; Klebanoff CA; Laskowski T; Melero I; Paulos CM; Pignata S; Ruella M; Svane IM; Taube JM; Fox BA; Hwu P; Puzanov I
J Transl Med; 2022 Jun; 20(1):257. PubMed ID: 35672823
[TBL] [Abstract][Full Text] [Related]
13. Role of CTLA Inhibition in Management of Non-Small Cell Lung Cancer.
Kerrigan K; Puri S
Curr Oncol Rep; 2022 Jan; 24(1):113-123. PubMed ID: 35060001
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant anti-programmed Death-1 immunotherapy by Pembrolizumab in resectable nodal positive stage II/IIIa non-small-cell lung cancer (NSCLC): the NEOMUN trial.
Eichhorn F; Klotz LV; Bischoff H; Thomas M; Lasitschka F; Winter H; Hoffmann H; Eichhorn ME
BMC Cancer; 2019 May; 19(1):413. PubMed ID: 31046714
[TBL] [Abstract][Full Text] [Related]
15. [Progress in Neoadjuvant Immunotherapies for Resectable Non-small Cell Lung Cancer].
Wang S; Mao Y
Zhongguo Fei Ai Za Zhi; 2020 May; 23(5):371-380. PubMed ID: 32283581
[TBL] [Abstract][Full Text] [Related]
16. Striving toward Improved Outcomes for Surgically Resectable Non-Small Cell Lung Cancer: the Promise and Challenges of Neoadjuvant Immunotherapy.
Gentzler RD; Riley DO; Martin LW
Curr Oncol Rep; 2020 Aug; 22(11):109. PubMed ID: 32803520
[TBL] [Abstract][Full Text] [Related]
17. The Promise of Neoadjuvant Immunotherapy and Surgery for Cancer Treatment.
O'Donnell JS; Hoefsmit EP; Smyth MJ; Blank CU; Teng MWL
Clin Cancer Res; 2019 Oct; 25(19):5743-5751. PubMed ID: 31040150
[TBL] [Abstract][Full Text] [Related]
18. Current Panorama and Challenges for Neoadjuvant Cancer Immunotherapy.
Benitez JC; Remon J; Besse B
Clin Cancer Res; 2020 Oct; 26(19):5068-5077. PubMed ID: 32434852
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant Immunotherapy: Leveraging the Immune System to Treat Early-Stage Disease.
Mittendorf EA; Burgers F; Haanen J; Cascone T
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-15. PubMed ID: 35714302
[TBL] [Abstract][Full Text] [Related]
20. A Computational Model of Neoadjuvant PD-1 Inhibition in Non-Small Cell Lung Cancer.
Jafarnejad M; Gong C; Gabrielson E; Bartelink IH; Vicini P; Wang B; Narwal R; Roskos L; Popel AS
AAPS J; 2019 Jun; 21(5):79. PubMed ID: 31236847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]